Phase II Study of Oxaliplatin, Xeloda, and cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

Trial Profile

Phase II Study of Oxaliplatin, Xeloda, and cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 28 Mar 2018 Planned End Date changed from 28 Jun 2018 to 28 Jun 2019.
    • 28 Mar 2018 Planned primary completion date changed from 28 Dec 2017 to 28 Dec 2018.
    • 08 Apr 2017 Planned End Date changed from 1 Jun 2017 to 28 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top